Bipolar disorders and quality of life: the impact of attention deficit/hyperactivity disorder and substance abuse in euthymic patients
- PMID: 18786727
- DOI: 10.1016/j.psychres.2007.06.016
Bipolar disorders and quality of life: the impact of attention deficit/hyperactivity disorder and substance abuse in euthymic patients
Abstract
Patients with bipolar disorders (BPD) display high rates of comorbidities, especially substance abuse (20-40%) and attention deficit/hyperactivity disorder (ADHD) (6%-20%). However, there are virtually no data evaluating the role of current ADHD on the global functioning of patients with BPD. The recent literature suggests that impairments in quality of life are a key prognostic feature for predicting the long course of BPD. The aim of this study was to investigate the intrinsic impact of adult ADHD and substance abuse in patients with BPD on levels of social adaptation, functioning and vitality. Seventy-three outpatients with BPD I or II, all euthymic and being treated with mood stabilizers, were evaluated using the following measures: 1) the Diagnostic Interview of Genetics Study for DSM-IV criteria; 2) the ADHD Self-Report Scale (ASRS) (screening of adult ADHD); 3) measures of quality of life: social adaptation (Social Adjustment Scale Self-Report (SAS-SR)), well-being (Short Form 36 (SF-36) Health Survey), and the Brief Psychiatric Rating Scale. In this clinical sample, 30% met the ADHD criteria and 22% were substance abusers. The results showed that the presence of ADHD in BPD patients significantly predicted a low social functioning and adaptation by comparison with BPD patients without ADHD. By contrast, we failed to detect a significant impact of substance abuse on those functional outcomes. This is the first step towards improved screening for comorbidities and an understanding of their crucial role in the prognosis of the disorder, as well as in defining new multilevel therapeutic strategies.
Similar articles
-
Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up.J Affect Disord. 2009 May;115(1-2):27-35. doi: 10.1016/j.jad.2008.08.019. Epub 2008 Oct 8. J Affect Disord. 2009. PMID: 18845344
-
Is adult attention deficit hyperactivity disorder a valid diagnosis in the presence of high IQ?Psychol Med. 2009 Aug;39(8):1325-35. doi: 10.1017/S0033291708004959. Epub 2008 Dec 24. Psychol Med. 2009. PMID: 19105857
-
Co-morbidity of bipolar disorder in children and adolescents with attention deficit/hyperactivity disorder (ADHD) in an outpatient Turkish sample.World J Biol Psychiatry. 2009;10(4 Pt 2):488-94. doi: 10.1080/15622970902929876. World J Biol Psychiatry. 2009. PMID: 19401947
-
[Attention-deficit/hyperactivity disorder and substance abuse].Psychiatr Prax. 2003 May;30(4):182-6. doi: 10.1055/s-2003-39496. Psychiatr Prax. 2003. PMID: 12768521 Review. German.
-
Diagnosing attention-deficit/hyperactivity disorder in patients with substance use disorders.J Clin Psychiatry. 2007;68 Suppl 11:9-14. J Clin Psychiatry. 2007. PMID: 18307376 Review.
Cited by
-
The quality of life of adults with attention deficit hyperactivity disorder: a systematic review.Innov Clin Neurosci. 2012 May;9(5-6):10-21. Innov Clin Neurosci. 2012. PMID: 22808445 Free PMC article.
-
Prevalence and clinical correlates of co-morbid attention deficit hyperactivity disorder in euthymic adults with bipolar disorder: A cross-sectional study.Indian J Psychiatry. 2023 Nov;65(11):1129-1136. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_647_23. Epub 2023 Nov 24. Indian J Psychiatry. 2023. PMID: 38249150 Free PMC article.
-
Comorbidity and patterns of familial aggregation in attention-deficit/hyperactivity disorder and bipolar disorder in a family study of affective and anxiety spectrum disorders.J Psychiatr Res. 2020 Nov;130:355-361. doi: 10.1016/j.jpsychires.2020.08.017. Epub 2020 Aug 23. J Psychiatr Res. 2020. PMID: 32882577 Free PMC article.
-
Comorbidities in Youth with Bipolar Disorder: Clinical Features and Pharmacological Management.Curr Neuropharmacol. 2023;21(4):911-934. doi: 10.2174/1570159X20666220706104117. Curr Neuropharmacol. 2023. PMID: 35794777 Free PMC article. Review.
-
Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder.Can J Psychiatry. 2023 May;68(5):299-311. doi: 10.1177/07067437221099769. Epub 2022 Jun 16. Can J Psychiatry. 2023. PMID: 35711159 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous